BioSpecifics Technologies Corp. Price Target Raised to $28.00 at MKM Partners (BSTC)
Analysts at MKM Partners increased their target price on shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) from $24.50 to $28.00 in a research report issued to clients and investors on Thursday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. MKM Partners’ target price points to a potential upside of 25.34% from the company’s current price.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) traded up 0.63% during mid-day trading on Thursday, hitting $22.34. 13,430 shares of the company’s stock traded hands. BioSpecifics Technologies Corp. has a one year low of $14.55 and a one year high of $23.75. The stock has a 50-day moving average of $21.80 and a 200-day moving average of $19.08. The company has a market cap of $141.6 million and a price-to-earnings ratio of 33.13.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.13. Analysts expect that BioSpecifics Technologies Corp. will post $0.69 EPS for the current fiscal year.
Separately, analysts at JMP Securities initiated coverage on shares of BioSpecifics Technologies Corp. in a research note to investors on Tuesday, October 22nd. They set an “outperform” rating and a $28.00 price target on the stock.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.